[go: up one dir, main page]

WO2008133129A1 - Agent thérapeutique pour le glaucome renfermant un agoniste du récepteur a2a de l'adénosine en tant que principe actif - Google Patents

Agent thérapeutique pour le glaucome renfermant un agoniste du récepteur a2a de l'adénosine en tant que principe actif Download PDF

Info

Publication number
WO2008133129A1
WO2008133129A1 PCT/JP2008/057394 JP2008057394W WO2008133129A1 WO 2008133129 A1 WO2008133129 A1 WO 2008133129A1 JP 2008057394 W JP2008057394 W JP 2008057394W WO 2008133129 A1 WO2008133129 A1 WO 2008133129A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
ring
glaucoma
adenosine
therapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/057394
Other languages
English (en)
Japanese (ja)
Inventor
Atsushi Shimazaki
Noriko Kawabata
Tomoko Kirihara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Santen Pharmaceutical Co Ltd
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of WO2008133129A1 publication Critical patent/WO2008133129A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)

Abstract

GW-328267, UK-432097 ou un composé représenté par la formule générale (1) ou l'un de ses sels, qui est un agoniste du récepteur A2A de l'adénosine, présente un excellent effet hypotenseur oculaire dans le test sur la diminution de la pression oculaire et il est donc utile en tant qu'agent prophylactique ou thérapeutique pour le glaucome ou l'hypertension oculaire. Dans la formule générale, W représente un atome d'hydrogène ou un groupe représenté par la formule générale (8); le cycle A représente un cycle benzène, un cycle pyridine, un cycle pyrazole, un cycle imidazole, un cycle cyclohexane ou analogues; X représente une liaison simple, O-CH2-CH2, NH-NH=CH, NH-CH2-CH2, CO-NH-CH2 ou analogues; Y représente CH ou N; Z représente CH2 ou O; R1 représente un atome d'hydrogène, un atome d'halogène, un groupe alkyle, un groupe alkylaminocarbonyle ou analogues; R2 représente un groupe hydroxyalkyle, un groupe alkylamino, un groupe alkylaminocarbonyle, un groupe triazolyle ou analogues; et R3 représente un atome d'hydrogène, un groupe alkyle ou analogues.
PCT/JP2008/057394 2007-04-16 2008-04-16 Agent thérapeutique pour le glaucome renfermant un agoniste du récepteur a2a de l'adénosine en tant que principe actif Ceased WO2008133129A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007106917 2007-04-16
JP2007-106917 2007-04-16

Publications (1)

Publication Number Publication Date
WO2008133129A1 true WO2008133129A1 (fr) 2008-11-06

Family

ID=39925585

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/057394 Ceased WO2008133129A1 (fr) 2007-04-16 2008-04-16 Agent thérapeutique pour le glaucome renfermant un agoniste du récepteur a2a de l'adénosine en tant que principe actif

Country Status (2)

Country Link
JP (1) JP2008285478A (fr)
WO (1) WO2008133129A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010524933A (ja) * 2007-04-16 2010-07-22 参天製薬株式会社 アデノシン誘導体を有効成分として含有する緑内障治療剤

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220332750A1 (en) * 2019-06-21 2022-10-20 Academy Of Military Medical Sciences Adenosine compound, its pharmaceutically acceptable salt or its stereoisomer and use thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06128281A (ja) * 1992-04-24 1994-05-10 Whitby Res Inc ヒドラゾアデノシン類
WO2000012098A1 (fr) * 1998-09-01 2000-03-09 Yamasa Corporation Compositions medicinales pour le traitement des maladies oculaires
JP2002518510A (ja) * 1998-06-23 2002-06-25 グラクソ グループ リミテッド ２−（プリン−９−イル）−テトラヒドロフラン−３，４−ジオール誘導体
JP2003506461A (ja) * 1999-06-22 2003-02-18 スィーヴィー セラピューティクス インコーポレイテッド Ｎ−ピラゾールａ２ａ受容体アゴニスト
JP2004508284A (ja) * 2000-02-18 2004-03-18 ファイザー・インク プリン誘導体

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06128281A (ja) * 1992-04-24 1994-05-10 Whitby Res Inc ヒドラゾアデノシン類
JP2002518510A (ja) * 1998-06-23 2002-06-25 グラクソ グループ リミテッド ２−（プリン−９−イル）−テトラヒドロフラン−３，４−ジオール誘導体
WO2000012098A1 (fr) * 1998-09-01 2000-03-09 Yamasa Corporation Compositions medicinales pour le traitement des maladies oculaires
JP2002173427A (ja) * 1998-09-01 2002-06-21 Yamasa Shoyu Co Ltd 眼疾患治療用医薬組成物
JP2003506461A (ja) * 1999-06-22 2003-02-18 スィーヴィー セラピューティクス インコーポレイテッド Ｎ−ピラゾールａ２ａ受容体アゴニスト
JP2004508284A (ja) * 2000-02-18 2004-03-18 ファイザー・インク プリン誘導体

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KONNO T. ET AL.: "Effect of 2-(6-cyano-1-hexyn-1-yl)adenosine on ocular blood flow in rabbits", LIFE SCIENCE, vol. 80, no. 12, February 2007 (2007-02-01), pages 1115 - 1122, XP005891969 *
KONNO T.: "Role of adenosine in intraocular pressure", NIPPON YAKURIGAKU ZASSHI, vol. 123, no. 4, 2004, pages 289 - 294 *
MASAYUKI U. ET AL.: "2-Aralkoxyadenosines: potent and selective agonists at the coronary artery A2 adenosine receptor", J. MED. CHEM., vol. 34, 1991, pages 1340 - 1344, XP002961133, DOI: doi:10.1021/jm00108a015 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010524933A (ja) * 2007-04-16 2010-07-22 参天製薬株式会社 アデノシン誘導体を有効成分として含有する緑内障治療剤

Also Published As

Publication number Publication date
JP2008285478A (ja) 2008-11-27

Similar Documents

Publication Publication Date Title
WO2005080384A3 (fr) Dérivé du benzimidazole et ses utilisations
WO2005075458A8 (fr) Derives de pyrimidine utilises en tant qu'antagonistes de recepteurs d'orexine
MX2009013626A (es) DERIVADO DE 17ß-CIANO-18A-HOMO-19-NOR-ANDROST-4-ENO, SU USO Y MEDICAMENTO QUE LO CONTIENE.
WO2008006043A3 (fr) Dérivés d'acide substitués pouvant être employés en tant qu'agents anti-athérosclérotiques, anti-dyslipidémiques, anti-diabétiques et anti-obésité, et méthode
WO2002076950A3 (fr) Procede et composes de traitement presentant une activite selective similaire a celle d'agonistes des recepteurs adrenergiques alpha 2b ou 2b/2c
WO2008096829A1 (fr) Composés tricycliques
WO2009072621A1 (fr) Composé dihydroazole substitué et agent antiparasitaire
NO20060154L (no) Imidazolyl-derivater
NO20051411L (no) Pyrazolderivater, medisinske sammensetninger inneholdende slike, medisinsk bruk derav samt intermediater til fremstilling derav
MY141559A (en) Triazole derivatives as tachykinin receptor antagonists
ATE388958T1 (de) 4'-c-substituierte 2-haloadenosinderivate
TW200738667A (en) Preparation method for dioxan-2-ylalkylcarbamate derivatives and intermediate thereof
WO2009035067A1 (fr) Agonistes des récepteurs des glucocorticoïdes constitués de dérivés de la 1,3,3-triméthyle-7-phényle-3,4-dihydro-1h-quinoxaline-2-one
WO2009038064A1 (fr) Dérivé hétérocyclique à activité inhibitrice sur la 11β-hydroxystéroïde déshydrogénase de type i
WO2008146914A1 (fr) Composition hétérocyclique
WO2009095792A3 (fr) Dérivés d'hétéroarylamide diazépinopyrimidone substitués
NO20072753L (no) 3-Etylidenhydrazinosubstituerte heterocykliske forbindelser som trombopoietinreseptoraktivatorer
MX2010001566A (es) Derivado de aminopirazolamida.
MX2009011076A (es) Agente terapeutico para glaucoma que contiene derivado de adenosina como ingrediente activo.
WO2008149834A1 (fr) Dérivé de pyrimidodiazépinone
NZ552137A (en) New 4-benzylidene-piperidin derivatives
TW200606152A (en) Piperidine compound and process for preparing the same
WO2005003087A3 (fr) Composes nouveaux utiles comme agents anti-bacteriens
EP1854789A4 (fr) Derive de quinazoline possedant une activite inhibitrice vis-a-vis de la tyrosine kinase
WO2008133129A1 (fr) Agent thérapeutique pour le glaucome renfermant un agoniste du récepteur a2a de l'adénosine en tant que principe actif

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08740475

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08740475

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP